HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University

This study has been completed.
Sponsor:
Collaborators:
Johns Hopkins University
University of North Carolina, Chapel Hill
Vanderbilt University
Pfizer
Information provided by (Responsible Party):
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT01339416
First received: March 16, 2011
Last updated: March 14, 2014
Last verified: March 2014
Results First Received: March 14, 2014  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Retrospective
Conditions: HIV
AIDS

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited and analyzed retrospectively from 3 clinical sites in the United States of America (Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Participants Participants who were diagnosed with Human immunodeficiency virus (HIV) infection and received HIV care during January 1, 2000 through December 31, 2010 (574 weeks) with follow-up extended up to 31st December 2011 (up to 626 weeks).

Participant Flow:   Overall Study
    All Participants  
STARTED     8202  
COMPLETED     8202  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Analysis population included all participants enrolled in the study.

Reporting Groups
  Description
All Participants Participants who were diagnosed with Human immunodeficiency virus (HIV) infection and received HIV care during January 1, 2000 through December 31, 2010 (574 weeks) with follow-up extended up to 31st December 2011 (up to 626 weeks).

Baseline Measures
    All Participants  
Number of Participants  
[units: participants]
  8202  
Age  
[units: years]
Median ( Inter-Quartile Range )
  39  
  ( 32 to 46 )  
Gender  
[units: participants]
 
Female     2348  
Male     5854  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Incidence Rate of Malignancies   [ Time Frame: Up to Week 626 ]

2.  Primary:   Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections   [ Time Frame: Up to Week 626 ]

3.  Primary:   Incidence Rate of Myocardial Infarction   [ Time Frame: Up to Week 626 ]

4.  Primary:   Incidence Rate of Liver Failure   [ Time Frame: Up to Week 626 ]

5.  Primary:   Incidence Rate of Viral Encephalitis   [ Time Frame: Up to Week 626 ]

6.  Secondary:   Incidence Rate of Rhabdomyolysis   [ Time Frame: Up to Week 626 ]

7.  Secondary:   Incidence Rate of Death   [ Time Frame: Up to Week 626 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description Due to the retrospective observational nature of study individual adverse events (AEs) were not planned to be collected and reported but only the pre-defined AEs which are represented as clinical endpoints reported in the outcome measure section.

Frequency Threshold
Threshold above which other adverse events are reported   0%  

Reporting Groups
  Description
All Participants Participants who were diagnosed with Human immunodeficiency virus (HIV) infection and received HIV care during January 1, 2000 through December 31, 2010 (574 weeks) with follow-up extended up to 31st December 2011 (up to 626 weeks).

Other Adverse Events
    All Participants  
Total, other (not including serious) adverse events    
# participants affected / at risk     0/0  



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: ViiV Healthcare
ClinicalTrials.gov Identifier: NCT01339416     History of Changes
Other Study ID Numbers: A4001106
Study First Received: March 16, 2011
Results First Received: March 14, 2014
Last Updated: March 14, 2014
Health Authority: United States: Investigational Review Board